PURPOSE: We evaluated the safety and efficacy of zero ischemia, radio frequency ablation assisted tumor enucleation for renal cell carcinoma.
We report the incidence of complications, positive surgical margins, local recurrence, and progression-free and disease specific survival rates.
MATERIALS AND METHODS: We retrospectively reviewed data on 42 patients with renal cell carcinoma treated with zero ischemia laparoscopic radio frequency ablation assisted tumor enucleation between March 2006 and November 2009. Median age was 60 years (range 37 to 82) and 31 patients (73.8%) were male. The median greatest tumor dimension was 3.4 cm (range 1.8 to 6.1). The Mann-Whitney U, chi-square and Fisher exact tests were used to compare bleeding and complications. The paired t and Mann-Whitney U tests were used to compare glomerular filtration rates. The Kaplan-Meier method was used to calculate survival.
RESULTS: We found 32 tumors with a greatest dimension of 4 cm or less and 10 with a greatest dimension of 4 to 7 cm. Median blood loss was 82.5 ml (range 15 to 210). Overall 7 complications (16.6%) occurred, including postoperative fever in 4 cases (Clavien grade II) and prolonged urinary leakage in 3 (Clavien grade III). The PADUA (preoperative aspects and dimensions used for an anatomical) score was associated with prolonged urinary leakage (p = 0.03) but not with overall complications. No patient had positive surgical margins. The glomerular filtration rate did not differ before vs 12 months after surgery. Three-year cancer specific, cumulative and progression-free survival was 100%, 97.3% and 96.4%, respectively.
CONCLUSIONS: Zero ischemia, laparoscopic radio frequency ablation assisted tumor enucleation of renal cell carcinoma is a safe, effective nephron sparing treatment that provides excellent oncological and functional outcomes.
Written by:
Zhao X, Zhang S, Liu G, Ji C, Wang W, Chang X, Chen J, Li X, Gan W, Zhang G, Minervini A, Guo H. Are you the author?
Urology Department, The Affiliated Nanjing Drum Tower Hospital, Nanjing University Medical School, Jiangsu, People's Republic of China.
Reference: J Urol. 2012 Oct;188(4):1095-101.
doi: 10.1016/j.juro.2012.06.035
PubMed Abstract
PMID: 22901568
UroToday.com Renal Cancer Section
